RecruitingPhase 3NCT06592326

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

A Randomized, Controlled, Open-label, Multicenter Phase 3 Clinical Study of 9MW2821 in Combination With Toripalimab Versus Standard Chemotherapy in First-line Locally Advanced or Metastatic Urothelial Cancer

Sponsor

Mabwell (Shanghai) Bioscience Co., Ltd.

Enrollment

460 participants

Start Date

Aug 22, 2024

Study Type

INTERVENTIONAL

Conditions

Urothelial Carcinoma

Summary

This is a randomized, controlled, open-label, multicenter phase 3 clinical study to evaluate the efficacy, safety and immunogenicity of 9MW2821 combined with Toripalimab versus standard chemotherapy in first-line locally advanced or metastatic urothelial cancer.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria12

Sign the informed consent form approved by IEC.
Male or female subjects aged 18 to 80 years.
ECOG status: 0 or 1.
Histologically confirmed local advanced or metastatic urothelial cancer
Previously untreated with local advanced or metastatic urothelial cancer
At least one measurable lesion, according to RECIST V1.1.
Adequate tumor tissues submitted for test
Suitable for cisplatin/carboplatin-based chemotherapy assessed by investigator
Life expectancy for more than 12 weeks.
Adequate organ functions.
Proper contraception methods.
Willingness to follow the study procedures.

Exclusion Criteria15

History of another malignancy within 3 years.
History of autoimmune disease requiring systemic treatment within 2 years.
History of clinically significant cardiac/cerebrovascular diseases or thrombosis within 6 months.
Major surgery treated within 28 days; Any live vaccines got within 28 days; Radiotherapy or Intravesical therapy treated within 21 days; Traditional Chinese medicine or any potent CYP3A4 inducers/inhibitors taken within 14 days.
Lots of pleural fluid and ascites, uncontrolled bone pain or spinal compression existed within 14 days; Systemic treatment with active infection within 7 days.
Previously treated with PD-1, PD-L1, PD-L2, CTLA-4 inhibitors; Previously treated with ADCs which target Nectin-4 or are conjugated with payload MMAE; Organ transplantation or allogeneic hematopoietic stem cell transplantation in the past.
Clinical significantly toxicity Grade ≥ 2 (except alopecia and pigmentation) related to previous treatment.
Any situations adding the risk of severe dry eye, active keratitis or corneal ulcer, etc.
Peripheral neuropathy Grade ≥ 2.
Any other serious chronic or uncontrolled disease.
Uncontrolled central nervous system metastases or carcinomatous meningitis.
Active HBV/HCV/HIV infection, etc.
Known allergic sensitivity to any of the ingredients of the study drug.
History of drug abuse or mental illness.
Other conditions unsuitable into the study.